The US Federal Trade Commission has filed a new complaint against WPATH, this time with the backing of four state attorneys general. A federal judge already blocked the FTC's first attempt this year, finding WPATH in a strong position to prove the action is retaliation. The independence of medical organisations, and trans people's access to evidence-based care, is what hangs in the balance.

What has actually happened

On 17 June 2026, WPATH issued a statement confirming that the FTC had filed a new complaint, this time enlisting the attorneys general of Alaska, Iowa, Nebraska, and Texas. This is the second formal legal action the Trump administration has taken against WPATH in 2026. The first was an attempt by the FTC to demand protected information from the organisation. A federal district court struck that down, finding not only that the request was improper, but that WPATH was in a strong position to show the entire action was retaliation against a professional medical body for its clinical positions.

Rather than accept that ruling and step back, the administration has gone around it. The new complaint is brought through state-level actors, but WPATH is clear that the factual and legal problems are the same. The FTC is not a medical provider. It has no jurisdiction over WPATH's non-commercial speech. The standards WPATH publishes are clinical guidelines, not commercial products or deceptive trade practices. None of that changed because the complaint now has four state attorneys general attached to it.

Why this is happening

WPATH has been producing evidence-informed guidance for clinicians treating transgender and gender-diverse people for more than fifty years. Its Standards of Care, now in their eighth edition, represent the global consensus of specialists in trans healthcare. That is precisely why the current US administration is targeting them. If you want to make gender-affirming care harder to access, one route is to discredit or legally hobble the professional body whose guidelines doctors rely on to justify providing it.

The federal judge who blocked the first FTC attempt made this plain, finding that the government appeared to be acting out of pure retaliation as part of a relentless and targeted campaign to undermine gender-affirming care. That is not WPATH's characterisation, it is a federal court's finding. The administration's response was to file another complaint.

What is at stake for trans people

People sometimes ask me why a legal dispute between a US regulator and a professional association matters to someone in Manchester, or Melbourne, or Madrid. The answer is that WPATH's guidelines are what clinicians around the world point to when they make decisions about trans healthcare. They are the scaffolding that holds up evidence-based care in countries where domestic expertise is thin or political will is shaky. Undermining WPATH does not only affect trans people in the United States. It gives every government that wants to restrict gender-affirming care a reason to say that the international consensus is contested, unreliable, or under investigation.

There is also something more immediate at stake. Trans people seeking care in the US right now are doing so in a climate where the administration is using federal agencies, state attorneys general, and legal harassment to make that care harder to access and harder to justify. The FTC action sends a message to individual clinicians: treat trans patients according to the guidelines, and the agency that brought down WPATH might come for you next. That chilling effect is part of the point.

What WPATH said, and why the words matter

WPATH's statement is worth reading carefully, because it is not the language of an organisation on the back foot. They described the FTC's first attempt as improper and struck down. They described the new complaint as baseless. They called the state attorneys general the administration's go-to, obedient state attorneys general. They named what is happening as an end-around after a legal defeat.

That is an organisation that fought in court, won, and is ready to fight again. The statement closes by reaffirming fifty years of commitment to evidence-informed care and promising to oppose this latest attack with the same expectation of success. I believe them, and I am glad they are standing firm.

The FTC has no place here

The FTC regulates deceptive commercial practices. WPATH publishes clinical guidelines through a non-profit professional association. The two things are categorically different, and the court already said so. What the administration is doing is using the machinery of federal and state government to harass a medical body into silence, or at least into caution, about a specific group of patients. That is a misuse of public authority, and it should be named as such.

Trans and gender-diverse people deserve the same quality of care as anyone else. Their clinicians deserve the same freedom to follow evidence-based guidelines as any other specialist. An independent professional body publishing those guidelines should not have to spend its resources defending itself in federal court because the government dislikes its conclusions.

WPATH has held the line. I hope the courts hold it with them.